Page 81 - 2020_02-Haematologica-web

Management of patients undergoing CAR T-cell therapy
2019;134(11):860-866.
20. Couzin-Frankel J. Supply of promising T
cell therapy is strained. Science. 2017;
356(6343):1112-1113.
21. Yakoub-Agha I, Ferrand C, Chalandon Y, et
al. [Prerequisite for hematopoietic cellular therapy programs to set up chimeric anti- gen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2017;104(12S):S43-S58.
22. Kohl U, Arsenieva S, Holzinger A, Abken H. CAR T cells in trials: recent achieve- ments and challenges that remain in the production of modified T cells for clinical applications. Hum Gene Ther. 2018;29(5): 559-568.
23. Park JH, Riviere I, Gonen M, et al. Long- term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449-459.
24. Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candi- dates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013;98(11):1726-1731.
25. Sim AJ, Jain MD, Figura NB, et al. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2019 Jun 5. [Epub ahead of print]
26. Maude SL. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2018;16(10):664-666.
27. Suryadevara CM, Desai R, Farber SH, et al. Preventing Lck activation in CAR T cells confers treg resistance but requires 4-1BB signaling for them to persist and treat solid tumors in nonlymphodepleted hosts. Clin Cancer Res. 2018;25(1):358-368.
28. Hirayama AV, Gauthier J, Hay KA, et al. The response to lymphodepletion impacts PFS in patients with aggressive non- Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133(17):1876- 1887.
29. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor- specific CD8+ T cells. J Exp Med. 2005;202(7):907-912.
30. Thiant S, Yakoub-Agha I, Magro L, et al. Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predic- tive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant. 2010;45(10):1546-1552.
31. Thiant S, Labalette M, Trauet J, et al. Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant. 2011;46(10):1374-1381.
32. Shank BR, Do B, Sevin A, et al. Chimeric antigen receptor T cells in hematologic malignancies. Pharmacotherapy. 2017;37 (3):334-345.
33. Turtle CJ, Hanafi L-AA, Berger C, et al. Immunotherapy of non-Hodgkin's lym- phoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.
34. Hay KA, Gauthier J, Hirayama AV, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-nega- tive CR after CD19 CAR T-cell therapy.
Blood. 2019;133(15):1652-1663.
35. Turtle CJ, Hay KA, Hanafi L-A, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19- specific chimeric antigen receptor–modi- fied T cells after failure of ibrutinib. J Clin
Oncol. 2017;35(26):3010-3020.
36. Neelapu SS, Tummala S, Kebriaei P, et al.
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62.
37. Maude SL, Shpall EJ, Grupp SA. Chimeric antigen receptor T-cell therapy for ALL. Hematology Am Soc Hematol Educ Program. 2014;2014(1):559-564.
38. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625- 638.
39. Yakoub-Agha I. Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Based on the recommenda- tions of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Curr Res Transl Med. 2018;66(2):57-58.
40. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modi- fied T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
41. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy per- sisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(25): 4129-4139.
42. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sus- tained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
43. Fishman JA, Hogan JI, Maus MV. Inflammatory and infectious syndromes associated with cancer immunotherapies. Clin Infect Dis. 2019;69(6):909-920.
44. Topp MS, Gockbuget N, Stein AS. Correction to Lancet Oncol 2015; 16: 60, 61. Safety and activity of blinatumomab for adult patients with relapsed or refractory B- precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 study. Lancet Oncol. 2015;16(4):e158.
45. Abboud R, Keller J, Slade M, et al. Severe cytokine-release syndrome after T cell- replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant. 2016;22(10):1851-1860.
46. Teachey DT, Grupp SA. Cytokine release syndrome after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(10):1736-1737.
47. Ureshino H, Ando T, Kizuka H, et al. Tocilizumab for severe cytokine-release syndrome after haploidentical donor trans- plantation in a patient with refractory Epstein-Barr virus-positive diffuse large B- cell lymphoma. Hematol Oncol. 2017;36(1):324-327.
48. Raj RV, Hamadani M, Szabo A, et al. Peripheral blood grafts for T cell-replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome. Biol Blood Marrow Transplant. 2018;24(8):1664-1670.
49. Frey N, Porter D. Cytokine release syn- drome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123-e127.
50. Giavridis T, van der Stegen SJC, Eyquem J,
et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731-738.
51. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differ- entially required for cytokine-release syn- drome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739-748.
52. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sus- tained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
53. Turtle CJ, Sommermeyer D, Berger C, et al. Therapy of B cell malignancies with CD19- specific chimeric antigen receptor-modified T cells of defined subset composition. Blood. 2014;124(21):384.
54. Lee DW, Kochenderfer JN, Stetler- Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lym- phoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-528.
55. Frey N. Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol. 2017;30(4):336-340.
56. Yakoub-Agha I, Moreau AS, Ahmad I, et al. [Management of cytokine release syn- drome in adult and pediatric patients undergoing CAR-T cell therapy for hema- tological malignancies: recommendation of the French Society of Bone Marrow and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2019;106(1S):S102-S109.
57. Rubin DB, Danish HH, Ali AB, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019;142(5):1334-1348.
58. Hay KA, Turtle CJ. Chimeric antigen recep- tor (CAR) T cells: lessons learned from tar- geting of CD19 in B-cell malignancies. Drugs. 2017;77(3):237-245.
59. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62.
60. Mahadeo KM, Khazal SJ, Abdel-Azim H, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2018;16(1):45-63.
61. Traube C, Silver G, Kearney J, et al. Cornell Assessment of Pediatric Delirium: a valid, rapid, observational tool for screening delir- ium in the PICU*. Crit Care Med. 2013;42 (3):656-663.
62. Cornillon J, Hadhoum N, Roth-Guepin G, et al. [Management of CAR-T cell-related encephalopathy syndrome in adult and pediatric patients: recommendations of the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2019 Jun 12. [Epub ahead of print]
63. Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen recep- tor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017-4023.
64. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
65. Hill JA, Li D, Hay KA, et al. Infectious com- plications of CD19-targeted chimeric anti- gen receptor-modified T-cell immunothera- py. Blood. 2017;131(1):121-130.
66. Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T- cell therapy in patients with B-cell lym- phoma and chronic hepatitis B or C virus infection. Blood. 2019;133(26):2800-2802.
haematologica | 2020; 105(2)
315